Jefferies Reiterates Buy Rating on Altimmune (ALT) as company enters 'execution stage'
Tweet Send to a Friend
Jefferies analyst Roger Song reiterated a Buy rating and $28.00 price target on Altimmune (NASDAQ: ALT)The analyst commented, "Altimmune is ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
